Why the study?
Does knowledge of acetylator phenotype help determine the appropriate dose of slow-release procainamide to achieve effective plasma levels?
Does knowledge of acetylator phenotype help determine the appropriate dose of slow-release procainamide to achieve effective plasma levels?
Knowledge of acetylator phenotype is important for dosing slow-release procainamide to achieve therapeutic plasma levels and avoid toxicity.
May guide slow-release procainamide dosing by acetylator status to achieve therapeutic levels safely; hypothesis-generating for contemporary arrhythmia care.
Slow-release procainamide given 8-hourly is shown to produce plasma levels generally accepted as giving effective prophylaxis against ventricular dysrhythmias occurring after recent myocardial infarction. Patients can be classified into 'slow' and 'fast' acetylators of procainamide. Knowledge of acetylator status is helpful in determining the dose of procainamide necessary to attain effective steady-state plasma levels while avoiding toxic ones. Acetylator status cannot be assessed accurately using sulphadimidine when the patients are also taking procainamide.
No takes yet. Share an insight, caveat, or question.
Campbell et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: